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Protocol
AbstrACt
Introduction In remote Aboriginal communities in 
Australia, scabies affects 7 out of 10 children before their 
first birthday. This is more than six times the rate seen 
in the rest of the developed world. Scabies infestation is 
frequently complicated by bacterial infection, leading to 
the development of skin sores and other more serious 
consequences, such as septicaemia and chronic heart and 
kidney diseases. Tea tree oil (TTO) has been used as an 
antimicrobial agent for several decades with proven clinical 
efficacy. Preclinical investigations have demonstrated 
superior scabicidal properties of TTO compared with widely 
used scabicidal agents, such as permethrin 5% cream 
and ivermectin. However, current data are insufficient 
to warrant a broad recommendation for its use for the 
management of scabies because previous studies were 
small or limited to in vitro observations.
Methods and analysis A pragmatic first trial will 
examine the clinical efficacy of a simple and low-cost TTO 
treatment against paediatric scabies and the prevention 
of associated secondary bacterial infections, with 1:1 
randomisation of 200 participants (Aboriginal children, 
aged 5–16 years and living in remote Australia) into active 
control (permethrin 5% cream) and treatment (5% TTO 
gel) groups. The primary outcome for the study is clinical 
cure (complete resolution). Secondary outcome measures 
will include relief of symptoms, recurrence rate, adverse 
effects, adherence to treatment regimen and patient 
acceptability.
Ethics and dissemination The project has received 
approvals from the University of Canberra Human 
Research Ethics Committee (HREC 16-133), Wurli-
Wurlinjang Health Service Indigenous subcommittee and 
the Aboriginal Medical Services Alliance Northern Territory 
reference group. The results of this study will be published 
in core scientific publications, with extensive knowledge 
exchange activities with non-academic audiences 
throughout the duration of the project.
trial registration ACTRN12617000902392; Pre-results.
IntroduCtIon
Scabies is a contagious, parasitic skin disease 
(dermatosis) caused by the acarine itch mite 
Sarcoptes scabiei var. hominis. Worldwide, there 
are 300 million cases of scabies each year, and 
the prevalence is as high as >60% in Aborig-
inal children and about 25% in Aboriginal 
adults in Australia. This is more than six times 
the rate seen in resource-poor communities 
worldwide but comparable with reported 
prevalence rates in Fiji.1–4 Scabies infestation 
has a negative impact on the quality of life of 
infected individuals, resulting in substantial 
stigmatisation and ostracism.5 6 
S. scabiei releases antigens into the outer
skin layer, resulting in local inflammatory and 
immune reactions, leading to severe itching 
(pruritus) and skin abrasions.7 8 Breaks in 
the epidermis serve as an entry point for 
bacteria, such as streptococci or staphylo-
cocci, and complement inhibitors released 
by scabies mites promote bacterial growth. 
strengths and limitations of this study
 ► The study will be conducted in collaboration with a
community-controlled Aboriginal Medical Service,
in a clinically and culturally sound way with gover-
nance and approvals by expert Aboriginal and Torres 
Strait Islander researchers and organisations.
 ► A range of outcomes will be monitored, including
clinical response, relief of symptoms, recurrence,
adverse effects, adherence to treatment and patient
acceptability.
 ► The educational and community support packages
delivered to participating communities as part of this 
study will facilitate the effective control of scabies
and offer long-term benefits to the community.
 ► This is a single-site study.
 ► Adherence to the treatment protocol may be subop-
timal in an Aboriginal community setting in remote
Australia; however, pragmatic strategies have been
incorporated in the study design to promote adher-
ence and limit attrition.
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This, in turn, can give rise to serious secondary infec-
tions.2 Superinfected lesions may develop into cellulitis or 
impetigo and may contribute to abscess formation. The 
sequelae predispose the individual to sepsis, and other 
serious consequences, such as chronic heart and kidney 
diseases.3 Australia’s Northern Territory has the highest 
documented incidence of rheumatic heart disease in the 
world. Both chronic heart and kidney diseases are signif-
icant causes of premature mortality among Aboriginal 
Australians, contributing to a considerable life expec-
tancy gap (10–17 years) between Aboriginal and non-Ab-
original people.7
Most current scabicides are potentially hazardous and 
are associated with moderate to serious cutaneous and 
systemic side effects.3 9–13 The safety of ivermectin (the 
sole oral therapy against scabies) has not been adequately 
established in the elderly, in patients with impaired liver 
function, in children aged <5 years or in pregnant women. 
No currently available acaricides possess ovicidal, antibac-
terial, anti-inflammatory and/or antipruritic properties. 
They are all ineffective at preventing treatment relapse 
arising from newly hatched mites, inflammatory skin reac-
tions due to mite antigens and pyodermal progression.
Emerging resistance to existing scabies treatments 
raises concerns regarding their continuing effective-
ness.1 14–17 In vitro sensitivity data for scabies mites over 
the last 10 years (Australian data) indicate that median 
survival times after treatment with the leading acaricides, 
ivermectin and permethrin, have increased twofold to 
threefold. Furthermore, treatment failures resulting from 
drug resistance have been documented.14 15
In developed countries, scabies infestation affects indi-
viduals with both low and high income and social status. 
The disease can also represent an expensive burden 
for communities or institutions experiencing outbreaks 
(such as long-term care facilities, nursing homes, hospi-
tals, schools and prisons).18 19 A low-cost, topical treatment 
would be extremely valuable, especially in developing 
countries with low incomes and overcrowding, where 
tropical and subtropical climates may promote the occur-
rence of scabies infestation.18 19
These public health concerns clearly demonstrate the 
need for further clinical studies into new antiscabietic 
agents. Tea tree oil (TTO) has shown promising results 
as an acaricide in preliminary in vitro studies.1 4 The 
therapeutic benefits of TTO-containing formulations 
for a range of dermatological conditions have been 
investigated in several small clinical studies, with mixed 
results.20 21 There have been concerns regarding the sensi-
tisation potential of neat TTO; however, when the oil is 
formulated in a suitable pharmaceutical base (cream/
ointment/gel) containing concentrations ≤25%, the risk 
of adverse skin reactions appears low.22 The potential 
of TTO toxicity in children is yet to be evaluated exten-
sively. A recent randomised clinical trial found that TTO 
(75% v/v) was well tolerated in the 30-day treatment of the 
viral infection molluscum contagiosum in children (mean 
age 6.3±5.1 years).23 Irritation and sensitising potential of 
TTO result largely from oxidised oil, due to elevated levels 
of peroxides and other TTO degradation products.24 In 
typical in-use conditions (amber glass bottle fitted with 
child-resistant polypropylene caps away from heat source 
and light), unformulated, neat TTO will have no appre-
ciable degradation for up to 12 months.22 24 Due to its high 
volatility, 90% of the TTO evaporates quickly from the skin 
surface, minimising the potential for TTO components to 
travel into the deeper layers of the skin and to be absorbed 
into the bloodstream. However, terpinen-4-ol, α-terpineol 
and 1,8-cineole can penetrate the epidermal layer of the 
skin sufficiently to produce antimicrobial, anti-inflamma-
tory and potentially acaricidal effects.20 25
TTO has been shown to possess insecticidal, acaricidal 
and repellent properties against a range of medical and 
veterinary pests, such as house dust mites,26 Demodex 
mites,27 28 swine mites29 30 and head lice.31 In vitro testing 
of TTO against human scabies mites demonstrated a supe-
rior result (60 min median survival time with 5% TTO) in 
comparison with standard treatments (150 min with iver-
mectin 100 µg/g; 120 min with permethrin 5%).4 32 TTO 
has also been used as a regular adjunct treatment (Royal 
Darwin Hospital, treatment protocol) in combination 
with benzyl benzoate and oral ivermectin for the manage-
ment of crusted scabies.4 33 Additional information on the 
therapeutic potential of TTO for scabies can be found in 
a recent review.21 However, current data are insufficient 
to warrant a broad recommendation for its use in the 
management of scabies.
The aim of this research is to determine the efficacy 
and safety of a TTO gel formulation (5% v/w TTO) 
versus the active comparator permethrin cream (Lyclear, 
5% w/w permethrin) in treating scabies infestation and 
preventing associated secondary bacterial infections in 
Aboriginal children living in remote Australia. In this 
study, we will assess whether the promising in vitro find-
ings with TTO translate into a meaningful clinical benefit 
when it is used under ‘real-world’ conditions, particularly 
in young Aboriginal people living in rural and remote 
communities, where scabies is common and causes signif-
icant morbidity and mortality. If proven effective, this 
treatment would prevent many Aboriginal children from 
needing hospitalisation due to scabies-driven compli-
cations, resulting in far-reaching outcomes among the 
Aboriginal communities within Australia and among 
afflicted children internationally.
Hence, we propose to perform an international 
first, investigator-initiated, independently sponsored, 
randomised controlled trial (RCT) of a 5% v/w TTO gel 
formulation for the treatment of scabies in Aboriginal 
children. The idea of evaluating the safety and clinical 
efficacy of TTO for the management of scabies in a RCT 
is novel and represents the first comprehensive inves-
tigation of TTO for the management of scabies. While 
Aboriginal people are intended as the primary beneficia-
ries of the proposed research, the pattern of scabies is 
analogous to that observed in resource-poor and under-
privileged communities globally.
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MEthods And AnAlysIs
study design
We intend to test the clinical efficacy of TTO to 
treat scabies infestation in children in a RCT, using a 
TTO-based 5% v/w gel similar to a TTO gel formulation 
previously tested in a clinical trial for cold sores.34 The 5% 
TTO gel contains approximately 14% poloxamer 407 gel, 
in addition to other excipients such as formulation stabi-
lisers and preservatives. Permethrin 5% cream has been 
selected as the active comparator due to its current status 
as the standard recommended therapy to treat scabies 
in children (and adults) in Australia. The design of this 
parallel group, two-arm, comparator-controlled, investi-
gator-blind, non-inferiority trial with 1:1 allocation ratio 
is summarised in figure 1. Recruitment will be staggered 
over 18 months (October 2017–April 2019) until 200 
participants are recruited. Our reporting of the protocol 
conforms to the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) 2013 checklist 
(online supplementary table S1 (SPIRIT Checklist) and 
online supplementary table S2 (WHO Trial Registration 
Data Set)).
The research methodology has been developed in 
consultation with, and is being implemented by, Aborig-
inal and non-Aboriginal health professionals. Exten-
sive community consultations occurred prior to the 
study protocol development. Furthermore, the Aborig-
inal subcommittee at the study site (the Wurli-Wurlin-
jang Aboriginal Community Health Service) and the 
Aboriginal Medical Services Alliance Northern Territory 
reference group were involved in developing the study 
protocol and have endorsed the study.
study site and personnel
The study will take place in Katherine, a remote town in 
Australia’s Northern Territory. It will be performed in 
collaboration with the Wurli-Wurlinjang Health Service 
(WWHS), a community-controlled Aboriginal medical 
service. This health service began in 1972 and, based on 
conservative estimates, has about 6400 regular Aborig-
inal clients. An additional 7000 Aboriginal people who 
live in over 25 remote Katherine region communities are 
counted as occasional clients.
We plan to employ Aboriginal people as research staff 
to help run the study, in the course of which they will 
have an opportunity to acquire the skills required to 
manage similar work in the future. All attempts will be 
made to ensure that the study is explained and conducted 
in a culturally appropriate manner. The study docu-
ments will be translated into three locally spoken aborig-
inal languages: East Side/West Side Kriol, Warlpiri and 
Gurindji. All research staff are aware of the guidelines 
of Good Clinical Practice and recognise the importance 
of undertaking the study in a culturally appropriate way. 
Non-Aboriginal research staff will complete cultural 
awareness training and will have a strong understanding 
that the research should not interfere with community 
values.
Potentially eligible participants will be seen by a team 
of Wurli staff including Aboriginal health practitioners 
(AHPs) and general practitioners (GPs). All involved 
staff will follow the Central Australian Rural Practitioners 
Association (CARPA) code of practice from the clinic 
manual for primary healthcare practitioners in remote 
and Aboriginal health services in central and northern 
Figure 1 Study flow diagram. TTO, tea tree oil.
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Australia.35 Study participants will be screened for eligi-
bility by an AHP at the WWHS. Other study-related duties 
performed by this AHP will include participant recruit-
ment, obtaining consent, clinical assessment, participant 
follow-up and site coordination, as well as coordination 
with other members of the study team (including inter-
state stakeholders). The AHP will also collaborate with 
two Aboriginal elders/local champions (members of 
the Wurli-Wurlinjang board of directors) to undertake 
community engagement initiatives (extensive commu-
nity consultations to promote study participation). Study 
recruitment and treatment will be overseen by a group of 
senior GPs at the WWHS.
Participants
The study will be confined to patients aged between 5 
and 16 years, whose legally responsible caregiver is willing 
for their child to participate. While there is a particu-
larly high burden of scabies among children aged less 
than 5 years, the safety of TTO in this age group has 
not been adequately established to include them in this 
trial. Informed consent (online supplementary appendix 
A1) will be sought from caregivers during the recruit-
ment process (prior to eligibility assessment or enrol-
ment). Caregivers will be expected to comply with the 
requirements of the protocol. This includes being able 
and willing to be contacted by telephone after the initial 
assessment and being able to provide written informed 
consent. Furthermore, the child’s assent to participate in 
the trial will be confirmed verbally and, if aged ≥12 years, 
the child will be asked for written assent (online supple-
mentary appendix A2). At the time of recruitment, the 
legally responsible caregiver will be asked whether the 
participating child will have access to regular shower facil-
ities during the treatment course (ie, days 1 and 8), and 
the need for a whole-body shower before application of 
treatment medications will be explained.
Participant inclusion criteria are (1) the presence of 
typical scabietic lesions (eg, papules, nodules or vesicles) 
at classical sites of predilection (specifically the following 
15 sites: face, head, palms, interdigits, sides of fingers, 
upper and lower extremities, wrists, axilla, nipple, umbil-
ical area and/or lower abdomen, genitalia, inguinal, 
buttocks and back area); (2) the presence of classical 
burrows on clinical examination; (3) nocturnal pruritus; 
(4) a history of scabies among family members or similar
symptoms among household contacts; and (5) access to
shower facilities and a telephone.
Exclusion criteria are (1) treatment with any topical 
scabicidal therapy in the month before entry into the 
study; (2) use of any topical or systemic treatment in the 
week before entry; (3) confirmed or suspected immuno-
suppressive or immunodeficient conditions, including 
HIV infection; (4) receipt of more than 2 weeks of immu-
nosuppressants or immune-modifying drugs (eg, prednis-
olone >0.5 mg/kg/day) in the preceding 4 weeks; (5) the 
presence of scabies with an atypical presentation, such as 
crusted scabies; (6) the presence of any other skin disease 
that could alter the picture of scabies; (7) the presence 
of a complicated secondary bacterial infection; or (8) a 
known history of allergy to any of the study medications 
(permethrin, TTO or other essential oils).
recruitment and enrolment
Recruitment and enrolment will occur at a single site. 
Participants will be recruited by an AHP while attending 
the WWHS clinic in Katherine. An outline of the recruit-
ment and enrolment process and a participant-based 
study timeline is given in figure 2.
Eligible participants will be offered adequate oppor-
tunities to discuss the study with the AHP on duty. 
The cultural integrity of the participant will be fully 
respected, and potential participants will not be 
coerced into participation. The medical care of poten-
tial participants will not be affected by their choice not 
to participate or to discontinue participation. Every 
effort will be made to ensure the potential participant 
fully understands the content of the Participant Infor-
mation Sheet (online supplementary appendix A3) 
and consent forms. Information sessions in the form of 
short videos (video tutorials with voice-overs in Aborig-
inal languages, if required) will be shown to the partic-
ipants and caregivers before the start of treatment to 
explain the nature of scabies, how it is transmitted from 
person to person, how to prevent recurrence and how 
to systematically wash their fomites (clothing, bedding 
or towels). The study team will also provide detailed 
written instructions (with the aid of flip cards) when 
dispensing the scabies formulations for home applica-
tion by parents/caregivers and household members.
randomisation, allocation concealment
After confirmation that the eligibility criteria have been 
met, the AHP will allocate participants to either the 
intervention or control group using a predetermined, 
age-stratified sequential serial number. He or she will 
then open the matched, sequentially numbered opaque 
envelope containing the treatment allocation instruc-
tions. The allocation ratio will be 1:1 active comparator 
(permethrin):test treatment (TTO), and the allocation 
sequence and treatment allocations will be concealed 
from trial participants and clinical assessors (AHPs) 
throughout the study. The simple randomisation schedule 
will be computer generated, and the randomisation will 
be kept secure (password protected) by an independent 
statistician (based at the University of Canberra) who is 
otherwise not part of the research team. The actual treat-
ment allocation will not be disclosed to the staff members 
responsible for patient care, treatment, evaluation and 
follow-up or to the study monitors. The treatment alloca-
tion will be concealed in all participant documents.
Medications and treatment
All treatments prescribed in connection with the study 
will be provided free of charge to the participants. 
Scabies treatments for day 1 and day 8 will be provided 
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concurrently at the first visit in well-labelled containers. 
Treatment will consist of application of the product by 
the participant or caregiver wearing plastic gloves and 
a gown following CARPA guidelines. Participants will 
be instructed to shower or bathe (with non-medicated 
soap) and have their bed linen changed before applying 
the treatment. The scabies formulations will be applied 
to every square inch of skin, from the posterior ear folds 
down over the entire body. This includes the intergluteal 
cleft, umbilicus, skin folds, palms and soles, and webs 
between fingers and toes. The area behind the ears will 
be given special attention while avoiding eyes and the 
mouth. Participants and caregivers will be instructed to 
clip the participant’s fingernails and toenails and apply 
the scabies formulations under nails. They will also be 
instructed to put on clean clothing after applying the 
treatment. Contaminated clothing and linens should be 
washed in the hot cycle of a washing machine and dried in 
Figure 2 Overview of the trial recruitment, treatment and assessment process. AE, adverse event; AHP, Aboriginal health 
practitioner.
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the hot cycle of a dryer for 10–20 min or dried under hot 
sunlight. If the trial medication is washed off during hand 
washing, toileting or perineal care, it must be reapplied.
The scabies treatment formulations will be applied at 
night after an evening shower/bath. In the case of the 
test medication (5% v/w TTO gel), the treatment will 
be applied on day 1 and day 8 and left on the body for 
8–12 hours each time. After this time, the children will 
shower/bathe (with non-medicated soap and water) to 
wash off the treatment. The comparator group medi-
cation (permethrin 5% cream, single application only) 
will also be applied as directed above on day 1, followed 
by a placebo treatment (identical standard formulation 
minus permethrin) on day 8. Participants will be advised 
not to use or mix any other scabies treatment with trial 
medications.
Test formulations (5% v/w TTO gel in an aqueous 
base) will be prepared following WHO Good Manufac-
turing Practices (GM, IDT Australia, VIC), and all formu-
lations will be supplied in appropriate child-safe medicine 
containers, labelled with the child’s identifiers and 
dosing (application) instructions. The trial medications 
will be stored in the clinic imprest at WWHS, and their 
supply will be supervised by the AHP. A 4-week expiry date 
will be set for all test formulations. On recruitment, the 
AHP will provide participants/caregivers (blinded) with 
sealed medication packs of identical appearance. The 
study participants and caregivers will be given additional 
personal protective equipment for direct patient care, 
including disposable long-sleeved gowns and gloves, in 
order to reduce the risk of transmission and prevent rein-
festation. Participants will also be provided with a sealable 
easily identifiable biohazard bag to dispose of gloves and 
gowns. They will be asked to return this bag to the clinic 
during their follow-up visits for safe disposal. Care and 
precautions will be exercised while dealing with partici-
pants to minimise transmission.35
To further prevent the spread of scabies, all other family 
contacts will be provided therapy with a standard-ap-
proved scabicide (permethrin 5%). This will be provided 
to caregivers in visually distinguishable containers with 
clear instructions using coloured labels to prevent medi-
cation errors. Crusted scabies-infested house contacts will 
be identified by questioning parents/caregivers, and the 
AHP will alert the Northern Territory Centre for Disease 
Control for the appropriate public health response. 
Follow-up and clinical assessment
After giving consent, the parent or caregiver attending 
with the child will be asked a standard set of questions by 
the trained AHP to capture potentially important demo-
graphic details. Clinical evaluations (blinded to treat-
ment allocation) will be made by experienced clinical 
investigators (trained AHP/Aboriginal nurse) following 
CARPA guidelines.
All participants will be followed up on days 9, 16 and 
30 and will be thoroughly examined by the same clinical 
staff member (AHP) as at baseline (day 1). At each of 
the four visits, examination of the entire body surface will 
be performed. The sites of lesions will be recorded on 
body diagram sheets, and lesions will be photographed 
using a standardised protocol.36 The notations of their 
appearance and whether they are new lesions or resid-
uals of original lesions will be determined by comparison 
with the pretreatment digital photographs. The severity 
of infestation will be graded based on the number of body 
sites showing typical scabietic lesions and recorded as 
mild infestation (<6 sites affected), moderate infestation 
(6–10 sites) or severe infestation (>10 sites).37 The extent 
of lesions on the entire body will be recorded as mild 
(≤10 lesions), moderate (11–49 lesions) or severe (≥50 
lesions).38 39 Trial data collection forms can be obtained 
on request from the corresponding author.
The primary outcome measure in this study is the clin-
ical cure of scabies at the end of the 30-day observation 
period. Outcome assessments will be conducted by inves-
tigators blinded to treatment allocation. The principal 
investigator or coinvestigators will assess cure by referring 
to target site photographs and marked body diagrams 
after data collection is complete. Cure is defined as the 
absence of new lesions, and all old lesions healed, on day 
30 (residual, dry, non-inflammatory papules will not be 
considered to be active).37 Treatment failure is defined 
as the presence of new or unhealed lesions on day 30 in 
a participant who was not considered to be cured on day 
16.
The secondary outcomes that will be investigated in this 
study are the rate of scabies recurrence, relief of pruritus, 
pyodermal progression (development of secondary bacte-
rial infections), adherence to the treatment regimen, the 
frequency/severity of adverse events (AEs) and patient 
acceptability of the treatment. Recurrence rate (or rate 
of scabies reinfestation) will be measured by determining 
the number of participants who are completely clear at 
day 16 and develop new lesions by day 30. Pruritus will 
be evaluated using a 0–10 visual analogue scale, where 
0 represents ‘no itch’ and 10 represents ‘worst imagin-
able itch’. All participants will be followed up for 3 weeks 
post-intervention to assess pruritus. Antipruritic medi-
cation, if needed, will be given after this period. The 
proportion of children with secondary bacterial compli-
cations will be determined by having trained AHPs iden-
tify and grade the severity of infected skin sores. Severity 
will be stratified by researchers into mild impetigo (one 
purulent or crusted sore and <5 sores in total) or severe 
impetigo (two or more purulent or crusted sores or ≥5 
sores in total).40 Participants’ acceptability of treatments 
will be assessed during the three follow-up visits by asking 
participants and caregivers to rate the treatment in terms 
of effectiveness, side effects, convenience and overall 
satisfaction.
Adherence and retention
Innovative strategies will be employed to motivate partic-
ipants’ adherence to the treatment protocol and to 
increase retention. These include providing each trial 
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participant with a tablet with preset reminder alarms and 
preloaded engaging video tutorials in relevant Aborig-
inal languages to facilitate the correct and easy appli-
cation of trial medications. Furthermore, gift vouchers 
(prepaid telephone cards and/or grocery vouchers) will 
be given to participants who attend all follow-up visits to 
compensate for participant transport to the study centre 
for assessments. A limited supply of washing powder, chil-
drens clothing and bed linen will be provided to study 
participants to better control the scabies infestation in 
the local communities and to facilitate the accomplish-
ment of long-term treatment goals. 
The AHP will review each participant by phone to record 
any apparent adverse effects and to monitor adherence to 
the treatment protocol, such as washing of fomites and 
permethrin use by other household members. Phone 
calls will be made daily for 3 days following each treat-
ment application and every 5th day post treatment phase 
(figure 2). The participant/caregiver will also receive 
reminder SMS alerts in the afternoon on each treatment 
day and the day before each follow-up assessment. In 
cases where telephone follow-up is not successful, the 
AHP will undertake healthcare home visits to enhance 
participants’ adherence to the treatment protocol and to 
improve retention.
Participant compliance to the treatment protocols will 
be assessed objectively by weighing the tubes of medi-
cations prior to the supply and at the end of treatment. 
Parents/caregivers will be reminded by nursing staff to 
return the formulations and tablets at the second assess-
ment visit. At the completion of the trial, the tablet 
computers will be collected and donated to local schools 
in the participating trial region for educational purposes.
Monitoring of AEs
During each follow-up visit and telephone call, the partic-
ipants/caregivers will be asked about the occurrence of 
any solicited or unsolicited adverse reactions to the treat-
ment. This will be done using a prespecified list of AEs 
including local adverse reactions (swelling, stinging/
burning, itching, induration, erythema, sore eyes or 
conjunctivitis) and systemic adverse reactions (fever, 
nausea, vomiting, headache and dizziness). Medically 
significant AEs will be documented from randomisation 
until the end of the study (day 30).
The relationship between each AE and the trial medi-
cation will be determined by a medical doctor according 
to the following definitions: (1) related: the AE follows 
a reasonable temporal sequence from trial medication 
administration and it cannot reasonably be attributed 
to any other cause; (2) not related: the AE is probably 
produced by the participant’s clinical state or by other 
modes of therapy administered to the participant. All AEs 
that are observed by an investigator or member of the 
healthcare team, that are reported by the participant (in 
person or on the telephone) or that are recorded in the 
participant’s medical records will be detailed in the case 
report forms (CRFs), whether or not attributed to the 
trial medication. AEs considered related to the trial medi-
cation will be followed either until resolution or until the 
event is considered stable. The following information will 
be recorded where available: description, date of onset 
and end date, severity, expectedness, assessment of relat-
edness to trial medication, other suspect drug or device, 
action taken and whether the participant is withdrawn 
due to AE.
The investigator will use their clinical judgement to 
decide whether an AE is of sufficient severity to require 
the discontinuation of the participant’s study medication. 
A participant may also voluntarily withdraw from treat-
ment due to what he or she perceives as an intolerable 
AE. If either of these occurs, the participant will undergo 
an end of trial assessment and be given appropriate care 
under medical supervision until symptoms cease or the 
condition becomes stable.
Feasibility
The Katherine region is a uniquely suitable site at which 
to perform this trial because of its proximity to Aboriginal 
communities. The region is home to about 15 000 Aborig-
inal residents, 6400 of whom are regular clients at WWHS. 
Our team has already established a research collabora-
tion and agreement with the recruitment site (WWHS) 
to recruit participants (n=200) within the proposed time-
frame (18 months).
sample size
The study sample size was calculated based on previous 
observational studies, in vitro data on TTO and the inves-
tigators’ findings from similar trials.38 Calculations are 
based on the assumptions that permethrin 5% cream 
will have a 90% cure rate, and TTO 5% formulation will 
have an 80% cure rate at 15 days. Given an estimated 
10% difference in cure rate in favour of the comparator 
permethrin arm, a sample of 69 participants per arm 
(138 in total) is required to be 80% sure that the upper 
limit of a one-sided 95% CI will exclude a difference in 
favour of the permethrin arm of more than 25%, thus 
establishing non-inferiority between TTO and perme-
thrin. A larger sample would have permitted us to detect 
a smaller non-inferior difference (eg, 15% and 10%). 
However, it may not be practical to recruit a larger cohort 
without presenting preliminary clinical safety efficacy 
data, especially in children. The results will be considered 
significant if P≤0.05. The current study will recruit 200 
participants (100 in each arm, to allow for up to 30% attri-
tion, based on our previous studies).
statistical analysis
Data will be reported in accordance with the Consol-
idated Standards of Reporting Trials guidelines. A 
detailed analysis plan will be approved by all investiga-
tors prior to any data analysis. For each outcome, the 
number of evaluable children in each treatment group 
will be presented, and data analysts will be blinded 
to treatment allocation. Categorical variables will be 
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summarised using frequency and percentage. Contin-
uous variables will be first assessed for significant depar-
tures from normality using a Shapiro-Wilk test and 
summarised using mean and SD or median and IQR 
as appropriate. Significantly skewed variables will be 
further assessed for transformation and analysed para-
metrically or non-parametrically, as appropriate. Differ-
ences in cure rate between treatment arms groups will be 
presented with a corresponding 95% CI and one-sided 
P value. Kaplan-Meier estimates and a log-rank test will 
be used to compare time-to-event outcomes by treatment 
arm. Cox proportional hazards regression will be used 
to adjust the association between treatment arm and 
time-to-event outcomes for known or suspected baseline 
confounders. The baseline comparability of groups will 
be further assessed, using the centre as an adjustment 
factor. Hazard proportionality will be assessed through 
analysis of scaled Schoenfeld residuals.
To reduce bias, all analyses will be based on an 
‘intention to treat’ approach; analyses will include all 
randomised participants, whether treated or not, as well 
as any participants who have withdrawn prematurely or 
are poorly compliant. An a priori subgroup analysis will 
be performed by age group (<12 years vs 12–16 years). A 
test for interaction will be performed to evaluate differen-
tial treatment effects by subgroup. Sensitivity analyses will 
be conducted to compare: (1) the available data analysis 
with alternative assumptions about any missing data and 
(2) the 'treatment allocated' approach with 'treatment
received' approach.
study management
This study is being supported by funding provided 
through the University of Canberra Collaborative Indig-
enous Research Initiative ( UC- CIRI@ canberra. edu. au). 
The proposed Clinical Trial Management (CTM) group 
will consist of the coinvestigators (including the trial stat-
istician) and the data manager. They will hold budgeted 
bimonthly teleconferences to review the overall conduct 
of the study. The trial operations team will include the 
site coordinator and data manager. They will telecon-
ference monthly to discuss operational issues including 
data collection, cleaning and recruitment. Data will 
be collected on the study-specific CRFs. All data will 
be entered onto the password-protected online data-
base provided by WebSpirit, stored at the University of 
Canberra, Discipline of Pharmacy. All coinvestigators will 
have access to the final trial dataset. Data queries will be 
raised and data cleaned by the data manager/trial statis-
tician and site coordinators via WebSpirit. The indepen-
dent Data and Safety Monitoring Committee (DSMC) 
will be chaired by an independent paediatric infectious 
disease clinician and also include a pharmacist, a statisti-
cian and a representative from the Child Health Indige-
nous Reference Group (WWHS). This committee will be 
responsible for monitoring the safety of the trial and will 
meet approximately every 4 months.
Premature termination of the study
This study can be terminated at any stage at the discre-
tion of the trial sponsor (University of Canberra) or the 
principal investigator (JT) in consultation with the DSMC 
and CTM group. If the study is prematurely terminated, 
the principal investigator will immediately inform current 
trial participants and notify the relevant ethics committee 
within 15 days.
An interim analysis will be conducted by an indepen-
dent statistician after the 100th participant has reached 
study day 30 to allow the DSMC to assess the ongoing 
appropriateness of the trial. The statistician will present 
the data to the DSMC in an interim report, including a 
descriptive analysis of AEs considered related to study 
treatment, the number of deaths in each study group 
(along with causality) and the number of participants 
experiencing each medically significant AE occurring in 
the first 30 days of the study. The interim analysis will be 
descriptive, and no hypothesis testing or presentation of 
P values for group comparisons will be made. The results 
of the interim analysis will remain confidential and will 
not be shared with study investigators unless the DSMC 
feels it is necessary to do so.
Ethical considerations
While preclinical studies, including hospital and labo-
ratory-based investigations, provide grounds to expect 
a positive outcome for a TTO intervention, sufficient 
equilibrium exists to warrant an RCT of its use for scabies 
management in a community setting. Aboriginal liaison 
workers will be sought to assist in participant recruitment. 
Parental consent will be requested on the basis of a full 
explanation of known (or potential) risks and uncertainty 
of benefit. Participants will also be given the option to 
provide additional consent for their data to be used in 
future ancillary studies. 
The privacy of participants will be protected by appro-
priate collection and storage of data. Participants will be 
identified only by initials and a participant ID number 
on the CRFs and in any electronic databases. The data 
collection forms will be stored in locked filing cabinets 
in a locked office at the participating clinic until the end 
of the study period. All documents will only be acces-
sible by trial staff and authorised personnel. Documents 
containing personal information will not be stored elec-
tronically and will be anonymised as soon as it is practical 
to do so. Data collection forms will be held for at least 15 
years on University of Canberra servers, based on National 
Health and Medical Research Council guidelines. These 
will then be destroyed.
Participants enrolled in the study will be covered 
by the research sponsor (University of Canberra) for 
indemnity and/or compensation for negligent harm 
or non-negligent harm arising specifically from an acci-
dental injury and occurring as a consequence of the 
research subject’s participation in the trial.
A protocol amendment history will be maintained 
and updated as necessary throughout the trial (online 
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supplementary table S3). Independent audits of trial 
conduct will be conducted annually by authorised 
representatives from the sponsoring and/or host insti-
tutions. The processes audited will include participant 
recruitment, enrolment, allocation and assessment; 
reporting of harms; completeness, accuracy and time-
liness of data collection; and adherence to the Inter-
national Conference on Harmonisation Good Clinical 
Practice guidelines.
dissemination
Research feedback at the end of the project will be in 
a form that is useful and understandable and include 
both a verbal and written summary detailing the input 
received and project outcomes. A suitably qualified 
Aboriginal person will be employed to liaise between 
Aboriginal communities and the research team to 
disseminate the study results and feedback to the local 
communities at large. The results will also be provided 
to the council and relevant community organisations. 
The findings of this trial will be disseminated through 
peer-reviewed journals and national and international 
scientific meetings, as well as to the participating 
communities. The Aboriginal reference group and the 
study CTM group will monitor public dissemination of 
any research findings. All reports will be submitted to 
these two groups prior to any results being published or 
disseminated into the public domain.
The principal investigator will coordinate dissemi-
nation of data from this study. All publications based 
on this study will be provided for review by each study 
investigator prior to submission. Authorship will be 
determined in line with the Uniform Requirements 
for Manuscripts Submitted to Biomedical Journals 
published by the International Committee of Medical 
Journal Editors. The final decision on authorship of any 
publication will be the responsibility of the principal 
investigator.
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